Delcath Systems (NASDAQ:DCTH) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Delcath Systems (NASDAQ:DCTH) in a research report sent to investors on Friday, Marketbeat.com reports. They currently have a $22.00 price target on the stock.

A number of other equities research analysts also recently commented on the company. Stephens reiterated an “overweight” rating and issued a $25.00 price objective on shares of Delcath Systems in a report on Tuesday, August 6th. Craig Hallum assumed coverage on Delcath Systems in a report on Friday, June 28th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, StockNews.com downgraded Delcath Systems from a “hold” rating to a “sell” rating in a report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $21.50.

Delcath Systems Stock Down 2.0 %

DCTH stock opened at $11.05 on Friday. The company has a market cap of $307.04 million, a P/E ratio of -4.17 and a beta of 0.78. Delcath Systems has a twelve month low of $2.25 and a twelve month high of $11.74. The business has a fifty day moving average of $9.19 and a 200-day moving average of $7.79.

Delcath Systems (NASDAQ:DCTH) last released its earnings results on Monday, August 5th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.12). The firm had revenue of $7.77 million for the quarter, compared to the consensus estimate of $5.00 million. Delcath Systems had a negative return on equity of 312.48% and a negative net margin of 474.22%. During the same quarter in the previous year, the firm earned ($0.58) EPS. As a group, equities research analysts anticipate that Delcath Systems will post -1.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DCTH. Levin Capital Strategies L.P. grew its stake in Delcath Systems by 12.2% in the first quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock valued at $262,000 after acquiring an additional 5,969 shares during the period. Cubist Systematic Strategies LLC acquired a new position in Delcath Systems in the second quarter valued at about $370,000. Renaissance Technologies LLC acquired a new position in Delcath Systems in the second quarter valued at about $694,000. Marshall Wace LLP grew its stake in Delcath Systems by 7.0% in the second quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock valued at $776,000 after acquiring an additional 6,066 shares during the period. Finally, Legato Capital Management LLC acquired a new position in Delcath Systems in the second quarter valued at about $966,000. 61.12% of the stock is owned by institutional investors and hedge funds.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.